NMC
HQL

Nine Masts Capital’s abrdn Life Sciences Investors HQL Stock Holding History

Nine Masts Capital’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-24,277
Closed -$456K – 331
2018
Q2 		$456K Buy
+24,277
New +$457K 0.09% 119

Other funds holding HQL

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Cohen & Steers
Cohen & Steers New York $57.6B AUM 8.03% 1-Year Est. Return
CAN
Claraphi Advisory Network Aliso Viejo, United States $251M AUM 9.29% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

Nine Masts Capital's HQL Position: Q3 2018 in Review

Nine Masts Capital sold out of abrdn Life Sciences Investors (HQL) in Q3 2018, closing a stake of 24,277 shares — an estimated $456K sold.

Nine Masts Capital first reported a position in HQL in Q2 2018 and held it in 1 quarter. The position peaked at $456K in Q2 2018. 57 funds tracked by Wall St. Rank hold HQL as of Q3 2018.

  • Nine Masts Capital reported no remaining abrdn Life Sciences Investors position as of Q3 2018 after selling out during the quarter.
  • Nine Masts Capital sold 24,277 abrdn Life Sciences Investors shares in Q3 2018, an estimated $456K.
  • Nine Masts Capital first reported a position in abrdn Life Sciences Investors in Q2 2018 and held it in 1 quarter.
  • Nine Masts Capital's abrdn Life Sciences Investors position peaked at $456K in Q2 2018.
  • 57 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q3 2018.

Based on Nine Masts Capital's 13F filing for Q3 2018, filed 16 Nov 2018.